

**Table 1. Characteristics of included studies in Dudas (2018) and Zhang (2023)**

Author	Age (year) Mean ± SD	N at baseline (I/C)	Intervention	Dose (mg)	Duration (weeks)	Control	Outcome measure
<b><i>Dudas, 2018</i></b>							
An, 2017	74.3 ± 7.5	27/33	Escitalopram	5-15	12	Placebo	CSDD
Banerjee, 2011	80.0 ± 8.4	107/111	Sertraline	50-150	13	Placebo	CSDD
	79.0 ± 8.4	108/111	Mirtazapine	45			
de Vasconcelos Cunha, 2007	77.6 ± 6.4	14/17	Venlafaxine	37.5-131.25	6	Placebo	MADRS
Fuchs, 1993	80 <sup>a</sup>	64/63	Maprotiline	25-75	8	Placebo	GDS
Lysketsos, 2003	75.5 ± 9.5	24/20	Sertraline	95	12	Placebo	CSDD
Petracca, 1996	72.0 ± 7.3	11/10	Clomipramine	25-100	6	Placebo	HRSD
Petracca, 2001	70.2 ± 6.3	17/24	Fluoxetine	10-40	6	Placebo	HRSD
Reifler, 1989	72.0 ± 8.0	13/15	Imipramine	83 <sup>b</sup>	8	Placebo	HRSD
Rosenberg, 2010	77.3 ± 8.0	67/64	Sertraline	50-100	12	Placebo	CSDD
Roth, 1996	73.6 ± 8.4	511 <sup>c</sup>	Moclobemide	400	6	Placebo	HRSD
<b><i>Zhang (2023)</i></b>							
Choe, 2016	74.3 ± 7.1	28/29	Escitalopram	20	52	Placebo	Adverse events
Magai, 2000	88.4 ± 6.1	17/14	Sertraline	25-100	8	Placebo	CSDD
Mowla, 2007	69.2	41/40	Fluoxetine <sup>d</sup>	20	12	Placebo	HRSD
Munro, 2004	75.5 ± 9.7	23/18	Sertraline	25-150	12	Placebo	CSDD

---

*Abbreviations: AD = Alzheimer's disease; CSDD = Cornell scale for depression in dementia; GDS = global depression scale; HRSD = Hamilton rating scale for depression; MADRS = Montgomery-Asberg depression rating scale; NR = not reported. <sup>a</sup> Median age is presented. <sup>b</sup> Mean daily dose is presented. <sup>c</sup> N is only reported for the total study population. <sup>d</sup> Participants in the intervention group received fluoxetine in addition to rivastigmine.*